Hospitals, including those participating in the 340B Drug Pricing Program, are the true safety-net, not the pharmaceutical industry with its “skyrocketing prescription drug prices and huge profits,” AHA Executive Vice President Tom Nickels writes in an AHASTAT blog post today. Nickels notes that hospitals care for all patients regardless of their ability to pay, and they have provided more than $500 billion in uncompensated care since 2000. He also highlights that hospitals participating in the 340B program use savings from the program to “provide free or reduced-priced prescription drugs to poorer residents” and “reinvest in programs that enhance patient services and access to care.” Nickels also cites various reports detailing the rapid spike in the costs of prescription drugs, including a Centers for Medicare & Medicaid Services report showing that prescription drug spending increased 12.6% in 2014. For more on the 340B program, visit www.aha.org/protect340B.

Headline
Members of Congress and hospital and health system leaders today gathered for a briefing in Washington, D.C., to discuss how payment delays in Medicare…
Headline
Eli Lilly said June 1 it will deny 340B Drug Pricing Program discounts to providers that do not meet its documentation requirements by next week.In a statement…
Headline
The 4th U.S. Circuit Court of AppealsMay 28 agreed to rehear challenges to 340B contract pharmacy laws from West Virginia and Maryland. In April, a three-judge…
Headline
The Centers for Medicare & Medicaid Services May 28 issued a final rule making changes to the Increasing Organ Transplant Access Model beginning July 1.…
Headline
The Wall Street Journal today published a letter to the editor from AHA General Counsel Chad Golder responding to a May 7 editorial criticizing the 340B Drug…
Perspective
Public
Approximately 35 million Americans are enrolled in Medicare Advantage plans in 2026, and that number is expected to grow to about 45 million MA enrollees by…